Literature DB >> 28948999

16p11.2 deletion syndrome mice perseverate with active coping response to acute stress - rescue by blocking 5-HT2A receptors.

Chris M Panzini1, Daniel G Ehlinger1, Adele M Alchahin1, Yueping Guo1,2, Kathryn G Commons1.   

Abstract

In humans a chromosomal hemideletion of the 16p11.2 region results in variable neurodevelopmental deficits including developmental delay, intellectual disability, and features of autism spectrum disorder (ASD). Serotonin is implicated in ASD but its role remains enigmatic. In this study we sought to determine if and how abnormalities in serotonin neurotransmission could contribute to the behavioral phenotype of the 16p11.2 deletion syndrome in a mouse model (Del mouse). As ASD is frequently associated with altered response to acute stress and stress may exacerbate repetitive behavior in ASD, we studied the Del mouse behavior in the context of an acute stress using the forced swim test, a paradigm well characterized with respect to serotonin. Del mice perseverated with active coping (swimming) in the forced swim test and failed to adopt passive coping strategies with time as did their wild-type littermates. Analysis of monoamine content by HPLC provided evidence for altered endogenous serotonin neurotransmission in Del mice while there was no effect of genotype on any other monoamine. Moreover, we found that Del mice were highly sensitive to the 5-HT2A antagonists M100907, which at a dose of 0.1 mg/kg normalized their level of active coping and restored the gradual shift to passive coping in the forced swim test. Supporting evidence for altered endogenous serotonin signaling was provided by observations of additional ligand effects including altered forebrain Fos expression. Taken together, these observations indicate notable changes in endogenous serotonin signaling in 16p11.2 deletion mice and support the therapeutic utility of 5-HT2A receptor antagonists.
© 2017 International Society for Neurochemistry.

Entities:  

Keywords:  autism; dorsal raphe; hippocampus; monoamine; serotonin; swim

Mesh:

Substances:

Year:  2017        PMID: 28948999      PMCID: PMC5729115          DOI: 10.1111/jnc.14227

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  43 in total

1.  The cognitive and behavioral phenotype of the 16p11.2 deletion in a clinically ascertained population.

Authors:  Ellen Hanson; Raphael Bernier; Ken Porche; Frank I Jackson; Robin P Goin-Kochel; LeeAnne Green Snyder; Anne V Snow; Arianne Stevens Wallace; Katherine L Campe; Yuan Zhang; Qixuan Chen; Debra D'Angelo; Andres Moreno-De-Luca; Patrick T Orr; K B Boomer; David W Evans; Stephen Kanne; Leandra Berry; Fiona K Miller; Jennifer Olson; Elliot Sherr; Christa L Martin; David H Ledbetter; John E Spiro; Wendy K Chung
Journal:  Biol Psychiatry       Date:  2014-06-16       Impact factor: 13.382

2.  Hyperactivity and male-specific sleep deficits in the 16p11.2 deletion mouse model of autism.

Authors:  Christopher C Angelakos; Adam J Watson; W Timothy O'Brien; Kyle S Krainock; Thomas Nickl-Jockschat; Ted Abel
Journal:  Autism Res       Date:  2016-10-14       Impact factor: 5.216

3.  Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors.

Authors:  James S Sutcliffe; Ryan J Delahanty; Harish C Prasad; Jacob L McCauley; Qiao Han; Lan Jiang; Chun Li; Susan E Folstein; Randy D Blakely
Journal:  Am J Hum Genet       Date:  2005-07-01       Impact factor: 11.025

4.  Serotonin neuron abnormalities in the BTBR mouse model of autism.

Authors:  Yue-Ping Guo; Kathryn G Commons
Journal:  Autism Res       Date:  2016-08-01       Impact factor: 5.216

5.  5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.

Authors:  G Quesseveur; C Repérant; D J David; A M Gardier; C Sanchez; B P Guiard
Journal:  Exp Brain Res       Date:  2013-02-15       Impact factor: 1.972

6.  Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism.

Authors:  Guy Horev; Jacob Ellegood; Jason P Lerch; Young-Eun E Son; Lakshmi Muthuswamy; Hannes Vogel; Abba M Krieger; Andreas Buja; R Mark Henkelman; Michael Wigler; Alea A Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

Review 7.  The 5-HT2A serotonin receptor in executive function: Implications for neuropsychiatric and neurodegenerative diseases.

Authors:  Susana Aznar; Mona El-Sayed Hervig
Journal:  Neurosci Biobehav Rev       Date:  2016-02-15       Impact factor: 8.989

Review 8.  Cortical interneuron dysfunction in epilepsy associated with autism spectrum disorders.

Authors:  John Jacob
Journal:  Epilepsia       Date:  2015-12-19       Impact factor: 5.864

9.  Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling.

Authors:  Ryan T Strachan; Douglas J Sheffler; Belinda Willard; Michael Kinter; Janna G Kiselar; Bryan L Roth
Journal:  J Biol Chem       Date:  2008-12-22       Impact factor: 5.157

10.  Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome.

Authors:  Marko Uutela; Jesse Lindholm; Tomi Rantamäki; Juzoh Umemori; Kerri Hunter; Vootele Võikar; Maija L Castrén
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

View more
  8 in total

1.  Serotonin abnormalities in Dravet syndrome mice before and after the age of seizure onset.

Authors:  Paul G Hatini; Kathryn G Commons
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 2.  Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.

Authors:  Ansoo Lee; Hyunah Choo; Byungsun Jeon
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

3.  16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro.

Authors:  Hannah Pinson; Richard S Smith; Maria Sundberg; Kellen D Winden; Pooja Venugopal; Derek J C Tai; James F Gusella; Michael E Talkowski; Christopher A Walsh; Max Tegmark; Mustafa Sahin
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

4.  Drug-responsive autism phenotypes in the 16p11.2 deletion mouse model: a central role for gene-environment interactions.

Authors:  Neil Dawson; Judith A Pratt; Brian J Morris; Emma J Mitchell; David M Thomson; Rebecca L Openshaw; Greg C Bristow
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

5.  Altered Serotonin 2A (5-HT2A) Receptor Signaling Underlies Mild TBI-Elicited Deficits in Social Dominance.

Authors:  Sean M Collins; Christopher J O'Connell; Evan L Reeder; Sophia V Norman; Kainat Lungani; Poornima Gopalan; Gary A Gudelsky; Matthew J Robson
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

6.  Comprehensive Behavioral Phenotyping of a 16p11.2 Del Mouse Model for Neurodevelopmental Disorders.

Authors:  Joseph F Lynch; Sarah L Ferri; Christopher Angelakos; Hannah Schoch; Thomas Nickl-Jockschat; Arnold Gonzalez; William Timothy O'Brien; Ted Abel
Journal:  Autism Res       Date:  2020-08-28       Impact factor: 5.216

7.  Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD.

Authors:  Jessica J Walsh; Pierre Llorach; Daniel F Cardozo Pinto; Wendy Wenderski; Daniel J Christoffel; Juliana S Salgado; Boris D Heifets; Gerald R Crabtree; Robert C Malenka
Journal:  Neuropsychopharmacology       Date:  2021-07-08       Impact factor: 8.294

8.  p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse.

Authors:  Matthew J Robson; Meagan A Quinlan; Kara Gross Margolis; Paula A Gajewski-Kurdziel; Jeremy Veenstra-VanderWeele; Michael D Gershon; D Martin Watterson; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-08       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.